ATOPIC DERMATITIS (AD) is the most common form of eczema and appears as an itchy skin rash that can vary in appearance. It commonly waxes and wanes and may clear for long periods. AD usually develops in early childhood but may occur at any age. While there is no cure for AD, it is typically managed by avoiding irritation of the skin from harsh soaps and fragrances, moisturizing the skin especially after showers or baths, and applications of medicated creams and ointments.
Recently, two new breakthrough medications have become available for the treatment of AD. Eucrisa (crisaborole) is a steroid-free ointment for people with mild-to-moderate eczema and can be used on all skin areas, for adults and children as young as 2 years old. It blocks an inflammatory enzyme that is present in increased concentration in AD. Dupixent (dupilumab) is an injection treatment indicated for the treatment of adult patients with moderate to severe AD whose disease is not adequately controlled with topical prescription therapies and works by blocking the underlying inflammation in AD. These medications are important additions to our therapeutic options for treating AD.
